Eli Lilly deal shows there is high-quality IP in China for foreign businesses that are prepared to search it out
Suzhou-based biopharmaceuticals firm Innovent Biologics has entered into an alliance with Eli Lilly & Co which will see its cancer therapies developed and marketed worldwide by the US company in a deal potentially worth upwards of $456 million.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.